Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice

PLoS Biology

Volumn 14, Issue 4, 2016, Pages

  Murali, Sathish K ^a   Andrukhova, Olena ^a   Clinkenbeard, Erica L ^b   White, Kenneth E ^b   Erben, Reinhold G ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; PROTEINASE; PYROPHOSPHATE; TISSUE NONSPECIFIC ALKALINE PHOSPHATASE; UNCLASSIFIED DRUG; VITAMIN D; ALKALINE PHOSPHATASE 2, MOUSE; FGFR3 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PYROPHOSPHORIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BONE MINERALIZATION; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; GENE MUTATION; HUMAN; HYPOPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOMALACIA; PARACRINE SIGNALING; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; VITAMIN BLOOD LEVEL; WILD TYPE; X CHROMOSOME; X LINKED HYPOPHOSPHATEMIC RICKETS; ANIMAL; BLOOD; BONE; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENETICS; METABOLISM; SECRETION (PROCESS); VITAMIN D DEFICIENCY;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHATES; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FIBROBLAST GROWTH FACTORS; MICE; OSTEOCYTES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA, MESSENGER; VITAMIN D DEFICIENCY;

EID: 84964866427     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002427     Document Type: Article

References (59)

1. Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet. 1995;11: 130–6. 7550339
2. Holm IA, Huang X, Kunkel LM, Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet. 1997;60: 790–7. 9106524
3. Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet. 1997;6: 539–49. 9097956
4. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, et al. Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest. 1997;99: 1200–9. 9077527
5. Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B, cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics. 1996;36: 22–8. 8812412
6. Strom TM, Francis F, Lorenz B, Boddrich A, Econs MJ, Lehrach H, et al. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet. 1997;6: 165–71. 9063736
7. Ruchon AF, Marcinkiewicz M, Siegfried G, Tenenhouse HS, DesGroseillers L, Crine P, et al. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem. 1998;46: 459–68. 9524191
8. Erben RG, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B, Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res. 2005;20: 1149–60. 15940367
9. Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashita T, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res. 2011;26: 803–10. doi: 10.1002/jbmr.27520939065
10. Tenenhouse HS, X-linked hypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant. 1999;14: 333–41. 10069185
11. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348: 1656–63. 12711740
12. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280: 2543–9. 15531762
13. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014;6: 744–59. doi: 10.1002/emmm.20130371624797667
14. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19: 429–35. 15040831
15. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24: 1879–88. doi: 10.1359/jbmr.09050919419316
16. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444: 770–4. 17086194
17. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390: 45–51. 9363890
18. Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS, Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol. 2004;183: R1–R9. 15590969
19. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology. 2008;149: 1757–72. 18162525
20. McKee MD, Nanci A, Osteopontin and the bone remodeling sequence. Colloidal-gold immunocytochemistry of an interfacial extracellular matrix protein. Ann N Y Acad Sci. 1995;760: 177–89. 7785894
21. Barros NM, Hoac B, Neves RL, Addison WN, Assis DM, Murshed M, et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res. 2013;28: 688–99. doi: 10.1002/jbmr.176622991293
22. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38: 1310–5. 17033621
23. Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD, Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS ONE. 2014;9: e104154. doi: 10.1371/journal.pone.010415425089825
24. Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013;28: 899–911. doi: 10.1002/jbmr.181023129509
25. Ichikawa S, Austin AM, Gray AK, Econs MJ, A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. J Bone Miner Res. 2012;27: 453–60. doi: 10.1002/jbmr.54422006791
26. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98: 6500–5. 11344269
27. Bai X, Miao D, Li J, Goltzman D, Karaplis AC, Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145: 5269–79. 15284207
28. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23: 421–32. 15579309
29. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD, Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291: E38–E4916449303
30. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD, Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol. 1998;275: E700–E708. 9755091
31. Ecarot B, Glorieux FH, Desbarats M, Travers R, Labelle L, Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J Bone Miner Res. 1992;7: 523–30. 1319665
32. Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD, Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab. 2007;293: E1636–E1644. 17848631
33. Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG, FGF23 regulates bone mineralization in a 1,25(OH)2D3 and Klotho-independent manner. J Bone Miner Res. 2016;31: 129–42. doi: 10.1002/jbmr.260626235988
34. Russell RG, Bisaz S, Donath A, Morgan DB, Fleisch H, Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest. 1971;50: 961–9. 4324072
35. Lieben L, Masuyama R, Torrekens S, Van LR, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122: 1803–15. doi: 10.1172/JCI4589022523068
36. Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD, Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem. 2007;282: 15872–83. 17383965
37. Gurley KA, Chen H, Guenther C, Nguyen ET, Rountree RB, Schoor M, et al. Mineral formation in joints caused by complete or joint-specific loss of ANK function. J Bone Miner Res. 2006;21: 1238–47. 16869722
38. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL, Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164: 1199–209. 15039209
39. Miyagawa K, Yamazaki M, Kawai M, Nishino J, Koshimizu T, Ohata Y, et al. Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice. PLoS ONE. 2014;9: e93840. doi: 10.1371/journal.pone.009384024710520
40. Ducy P, Geoffroy V, Karsenty G, Study of osteoblast-specific expression of one mouse osteocalcin gene: characterization of the factor binding to OSE2. Connect Tissue Res. 1996;35: 7–14. 9084638
41. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19: 1842–4. 16123173
42. Bellows CG, Heersche JN, Aubin JE, Inorganic phosphate added exogenously or released from beta-glycerophosphate initiates mineralization of osteoid nodules in vitro. Bone Miner. 1992;17: 15–29. 1581703
43. Jay FF, Vaidya M, Porada SM, Andrukhova O, Schneider MR, Erben RG, Amphiregulin lacks an essential role for the bone anabolic action of parathyroid hormone. Mol Cell Endocrinol. 2015;417: 158–65. doi: 10.1016/j.mce.2015.09.03126427650
44. Clinkenbeard EL, Cass TA, Ni P, Hum JM, Bellido T, Allen MR, et al. Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia. J Bone Miner Res. 2016;
45. Addison WN, Nakano Y, Loisel T, Crine P, McKee MD, MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res. 2008;23: 1638–49. doi: 10.1359/jbmr.08060118597632
46. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, et al. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J. 2003;373: 271–9. 12678920
47. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34: 303–19. 14962809
48. Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, et al. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol. 2002;16: 2913–25. 12456809
49. Boskey A, Frank A, Fujimoto Y, Spevak L, Verdelis K, Ellis B, et al. The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice. Calcif Tissue Int. 2009;84: 126–37. doi: 10.1007/s00223-008-9201-y19082853
50. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002;99: 9445–9. 12082181
51. Wennberg C, Hessle L, Lundberg P, Mauro S, Narisawa S, Lerner UH, et al. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res. 2000;15: 1879–88. 11028439
52. Meyer RA, Jr.Meyer MH, Gray RW, Bruns ME, Evidence that low plasma 1,25-dihydroxyvitamin D causes intestinal malabsorption of calcium and phosphate in juvenile X-linked hypophosphatemic mice. J Bone Miner Res. 1987;2: 67–82. 3455158
53. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 2011;25: 2551–62. doi: 10.1096/fj.10-17781621507898
54. Mikuni-Takagaki Y, Kakai Y, Satoyoshi M, Kawano E, Suzuki Y, Kawase T, et al. Matrix mineralization and the differentiation of osteocyte-like cells in culture. J Bone Miner Res. 1995;10: 231–42. 7754802
55. Hong SH, Jiang X, Chen L, Josh P, Shin DG, Rowe D, Computer-Automated Static, Dynamic and Cellular Bone Histomorphometry. J Tissue Sci Eng. 2012;Suppl 1: 004. 25019033
56. Erben RG, Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem. 1997;45: 307–13. 9016319
57. Schenk R. Preparation of calcified tissues for light microscopy, 1984; Methods of calcified tissue preparation.
58. McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A, Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle. 2014;13: 1400–12. doi: 10.4161/cc.2840124626186
59. Jiang X, Ye M, Jiang X, Liu G, Feng S, Cui L, et al. Method development of efficient protein extraction in bone tissue for proteome analysis. J Proteome Res. 2007;6: 2287–94. 17488005